 ATLANTA, Feb. 18, 2021 GLOBE NEWSWIRE -- Alimera Sciences, Inc. NASDAQ: ALIM Alimera, a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema DME and non-infectious uveitis affecting the posterior segment NIPU, and will be marketed by Alimera and distributed by Nordic Prime. 